AGIOAGIOS PHARMACEUTICALS, INC.同业对比
AGIOS PHARMACEUTICALS, INC. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AGIO本股 | $2.0B#8 | — | 2.0x#5 | 37.6x#9 | 48.0%#5 | -161.3%#13 | -873.9%#11 | -40.3%#9 | — | — | -6.4%#10 | — |
| PBH | $2.2B#2 | 13.0x#1 | 1.1x#2 | 2.0x#4 | -4.3%#12 | -11.3%#10 | 28.4%#1 | 9.9%#2 | 5.9%#2 | 4#1 | -27.4%#12 | — |
| TRVI | $2.2B#1 | — | 6.9x#10 | — | — | 10.7%#9 | — | -13.3%#6 | — | — | 94.0%#3 | — |
| SRPT | $2.2B#3 | — | 1.4x#3 | 1.2x#3 | 4.3%#10 | -403.3%#14 | -37.5%#6 | -46.7%#10 | -73.0%#6 | — | 21.5%#9 | — |
| ZBIO | $2.2B#4 | — | 8.8x#12 | 217.6x#11 | 100.0%#4 | -140.6%#12 | -3830.6%#12 | -152.9%#14 | -296.6%#8 | — | 74.7%#5 | — |
| BHC | $2.1B#5 | — | — | 0.2x#1 | 6.7%#9 | 441.3%#2 | 17.7%#2 | — | 3.6%#3 | — | — | 16.6%#1 |
| NUVB | $2.1B#6 | — | 8.4x#11 | 34.0x#8 | 699.0%#2 | 64.0%#4 | -338.7%#10 | -80.6%#12 | -87.4%#7 | — | 85.7%#4 | — |
| RAPP | $2.0B#7 | — | 4.8x#8 | — | — | -42.4%#11 | — | -26.4%#8 | — | — | 61.6%#7 | — |
| ZYME | $2.0B#10 | — | 24.5x#13 | 18.6x#7 | 38.9%#7 | 33.9%#6 | -87.3%#7 | -100.9%#13 | — | — | 74.5%#6 | — |
| BHVN | $2.0B#9 | — | 162.9x#14 | — | — | 12.7%#8 | — | -6045.0%#15 | — | — | -10.5%#11 | — |
| PRGO | $1.9B#13 | — | 0.7x#1 | 0.4x#2 | -2.8%#11 | -729.7%#15 | -26.4%#5 | -56.7%#11 | -20.9%#4 | 4#1 | -31.4%#13 | 8.6%#2 |
| SEPN | $1.9B#12 | — | 4.8x#7 | 40.5x#10 | 4174.5%#1 | 31.9%#7 | -148.6%#9 | -12.6%#5 | — | — | 176.5%#1 | — |
| STOK | $1.9B#11 | — | 5.4x#9 | 10.1x#5 | 404.5%#3 | 92.3%#3 | -11.2%#4 | -2.0%#4 | — | — | 27.3%#8 | — |
| XNCR | $1.8B#14 | — | 3.6x#6 | 14.6x#6 | 13.7%#8 | 60.5%#5 | -141.4%#8 | -18.3%#7 | -31.5%#5 | — | 164.9%#2 | — |
| KLRA | $1.7B#15 | — | 1.5x#4 | — | — | — | — | 0.0%#3 | — | — | — | — |
| ANIP | — | 16.3x#2 | — | — | 43.8%#6 | 510.5%#1 | 12.6%#3 | 13.1%#1 | 16.9%#1 | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议